Stephan is the Chief Scientific Officer at Anokion, driving the technology forward from our research unit in Cambridge. He received his B.Sc. in Chemical Engineering from the University of Texas at Austin and moved to the EPFL for his doctorate in Bioengineering. During his thesis work in Jeff Hubbell’s group, he co-invented and developed the erythrocyte-binding tolerance technology that led to the founding of Anokion. Following completion of his PhD in Bioengineering, Stephan further advanced several design aspects of our core technology as a post-doctoral researcher.